Sevilla, Spain Apr 4, 2024 (Issuewire.com) - KeyZell, a Spanish biopharmaceutical company with subsidiaries in the United Kingdom, Australia, Thailand, and Mexico, is proud to announce its inclusion in the prestigious acceleration program by Bolsas y Mercados Españoles (BME) known as 'Entorno Pre-Mercado' (EpM). As a leader in developing innovative technologies to combat cancer, this partnership marks a significant step in its ongoing commitment to excellence and innovation in the field of oncology.
Designed for companies with high growth potential, EpM offers KeyZell the opportunity to expand its network, access strategic resources, and prepare for potential entry into regulated stock markets.
KeyZell's inclusion in EpM aligns with its ambitious expansion plan, including the upcoming initiation of clinical trials for triple-negative breast cancer and non-small cell lung cancer. Additionally, it has recently entered into an agreement with the Junta de Andalucía to validate its Artificial Intelligence and develop new tools for Oncological Precision Medicine.
Currently, KeyZell has two artificial intelligence (AI) platforms: O.P.S. (Oncology Precision System), with 89% accuracy, which aids in predicting the best personalized treatment to ensure the highest 5-year survival rate, and O.D.S. (Oncology Diagnostic System), an innovative tool that assists radiologists in detecting tumor masses with 93% accuracy and provides diagnosis within seconds. Both platforms are in the process of ISO 13485 certification and CE Marking.
KeyZell's inclusion in the EpM program underscores its ongoing commitment to innovation, excellence, advancing the fight against cancer, and creating shareholder value.
Media Contact
KeyZell
Source :KeyZell Holding SL
This article was originally published by IssueWire. Read the original article here.
